Atherosclerotic process, renovascular disease and outcomes from bench to bedside

Lilach O Lerman, Alejandro R. Chade

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Atherosclerotic renal artery stenosis has become an important cause of secondary hypertension and renal dysfunction in the aging population. Its presence increases cardiovascular morbidity and mortality independent of other atherosclerotic risk factors. Therefore, novel renoprotective strategies are needed to decrease the impact of this disease. RECENT FINDINGS: Although medical therapy can be effective in patients with atherosclerotic renal artery stenosis and mild renal dysfunction, revascularization is desirable for patients with target-organ injury. Technical developments (such as drug-eluting or low-profile stents and distal protection devices) have increased the safety and effectiveness of renal revascularization, but in a significant proportion of patients renal function is not fully restored. Recent experimental evidence suggests that atherosclerotic renal artery stenosis is associated with the activation of intrarenal fibrogenic and inflammatory pathways, oxidative stress, and microvascular remodeling, and blocking these mechanisms can improve renal hemodynamics and function. SUMMARY: Despite significant advances in revascularization techniques, it remains unclear why the kidney affected by atherosclerotic renal artery stenosis often does not improve or even progressively deteriorates. In addition to the restoration of blood flow, targeted interventions to attenuate injurious intrarenal mechanisms should probably become part of a comprehensive management plan to preserve the ischemic kidney.

Original languageEnglish (US)
Pages (from-to)583-587
Number of pages5
JournalCurrent Opinion in Nephrology and Hypertension
Volume15
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

Renal Artery Obstruction
Kidney
Renal Hypertension
Stents
Oxidative Stress
Hemodynamics
Morbidity
Safety
Equipment and Supplies
Mortality
Wounds and Injuries
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • Atherosclerosis
  • Ischemia
  • Renal artery stenosis
  • Renovascular hypertension
  • Revascularization

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Atherosclerotic process, renovascular disease and outcomes from bench to bedside. / Lerman, Lilach O; Chade, Alejandro R.

In: Current Opinion in Nephrology and Hypertension, Vol. 15, No. 6, 11.2006, p. 583-587.

Research output: Contribution to journalArticle

@article{01fd1ef5ddb643eebcf3543fbfc4cd0e,
title = "Atherosclerotic process, renovascular disease and outcomes from bench to bedside",
abstract = "PURPOSE OF REVIEW: Atherosclerotic renal artery stenosis has become an important cause of secondary hypertension and renal dysfunction in the aging population. Its presence increases cardiovascular morbidity and mortality independent of other atherosclerotic risk factors. Therefore, novel renoprotective strategies are needed to decrease the impact of this disease. RECENT FINDINGS: Although medical therapy can be effective in patients with atherosclerotic renal artery stenosis and mild renal dysfunction, revascularization is desirable for patients with target-organ injury. Technical developments (such as drug-eluting or low-profile stents and distal protection devices) have increased the safety and effectiveness of renal revascularization, but in a significant proportion of patients renal function is not fully restored. Recent experimental evidence suggests that atherosclerotic renal artery stenosis is associated with the activation of intrarenal fibrogenic and inflammatory pathways, oxidative stress, and microvascular remodeling, and blocking these mechanisms can improve renal hemodynamics and function. SUMMARY: Despite significant advances in revascularization techniques, it remains unclear why the kidney affected by atherosclerotic renal artery stenosis often does not improve or even progressively deteriorates. In addition to the restoration of blood flow, targeted interventions to attenuate injurious intrarenal mechanisms should probably become part of a comprehensive management plan to preserve the ischemic kidney.",
keywords = "Atherosclerosis, Ischemia, Renal artery stenosis, Renovascular hypertension, Revascularization",
author = "Lerman, {Lilach O} and Chade, {Alejandro R.}",
year = "2006",
month = "11",
doi = "10.1097/01.mnh.0000247494.77752.f4",
language = "English (US)",
volume = "15",
pages = "583--587",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Atherosclerotic process, renovascular disease and outcomes from bench to bedside

AU - Lerman, Lilach O

AU - Chade, Alejandro R.

PY - 2006/11

Y1 - 2006/11

N2 - PURPOSE OF REVIEW: Atherosclerotic renal artery stenosis has become an important cause of secondary hypertension and renal dysfunction in the aging population. Its presence increases cardiovascular morbidity and mortality independent of other atherosclerotic risk factors. Therefore, novel renoprotective strategies are needed to decrease the impact of this disease. RECENT FINDINGS: Although medical therapy can be effective in patients with atherosclerotic renal artery stenosis and mild renal dysfunction, revascularization is desirable for patients with target-organ injury. Technical developments (such as drug-eluting or low-profile stents and distal protection devices) have increased the safety and effectiveness of renal revascularization, but in a significant proportion of patients renal function is not fully restored. Recent experimental evidence suggests that atherosclerotic renal artery stenosis is associated with the activation of intrarenal fibrogenic and inflammatory pathways, oxidative stress, and microvascular remodeling, and blocking these mechanisms can improve renal hemodynamics and function. SUMMARY: Despite significant advances in revascularization techniques, it remains unclear why the kidney affected by atherosclerotic renal artery stenosis often does not improve or even progressively deteriorates. In addition to the restoration of blood flow, targeted interventions to attenuate injurious intrarenal mechanisms should probably become part of a comprehensive management plan to preserve the ischemic kidney.

AB - PURPOSE OF REVIEW: Atherosclerotic renal artery stenosis has become an important cause of secondary hypertension and renal dysfunction in the aging population. Its presence increases cardiovascular morbidity and mortality independent of other atherosclerotic risk factors. Therefore, novel renoprotective strategies are needed to decrease the impact of this disease. RECENT FINDINGS: Although medical therapy can be effective in patients with atherosclerotic renal artery stenosis and mild renal dysfunction, revascularization is desirable for patients with target-organ injury. Technical developments (such as drug-eluting or low-profile stents and distal protection devices) have increased the safety and effectiveness of renal revascularization, but in a significant proportion of patients renal function is not fully restored. Recent experimental evidence suggests that atherosclerotic renal artery stenosis is associated with the activation of intrarenal fibrogenic and inflammatory pathways, oxidative stress, and microvascular remodeling, and blocking these mechanisms can improve renal hemodynamics and function. SUMMARY: Despite significant advances in revascularization techniques, it remains unclear why the kidney affected by atherosclerotic renal artery stenosis often does not improve or even progressively deteriorates. In addition to the restoration of blood flow, targeted interventions to attenuate injurious intrarenal mechanisms should probably become part of a comprehensive management plan to preserve the ischemic kidney.

KW - Atherosclerosis

KW - Ischemia

KW - Renal artery stenosis

KW - Renovascular hypertension

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=33750220329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750220329&partnerID=8YFLogxK

U2 - 10.1097/01.mnh.0000247494.77752.f4

DO - 10.1097/01.mnh.0000247494.77752.f4

M3 - Article

C2 - 17053471

AN - SCOPUS:33750220329

VL - 15

SP - 583

EP - 587

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 6

ER -